Total tissue factor pathway inhibitor and venous thrombosis: The longitudinal investigation of thromboembolism etiology

Thrombosis and Haemostasis

Volumn 104, Issue 2, 2010, Pages 207-212

  Zakai, Neil A ^a   Lutsey, Pamela L ^b   Folsom, Aaron R ^b   Heckbert, Susan R ^c   Cushman, Mary ^a  

^a University of Vermont Colchester Research Facility   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Epidemiologic studies; Tissue factor pathway inhibitor; Venous thrombosis

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; D DIMER; PROTHROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

BIOLOGICAL MARKERS; BLOOD COAGULATION; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DOWN-REGULATION; FEMALE; HUMANS; LIPOPROTEINS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 77955450362     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-10-0693     Document Type: Article

References (22)

1. Lindahl AK. Tissue factor pathway inhibitor: a potent inhibitor of in-vitro coagulation and in-vivo thrombus formation. Curr Opin Lipidol 1994; 5: 434-439.
2. Holst J, Lindblad B, Bergqvist D, et al. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin. Thromb Haemost 1994; 71: 214-219. (Pubitemid 24047330)
3. Dahm A, Rosendaal FR, Andersen TO, et al. Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state. Br J Haematol 2006; 132: 333-338. (Pubitemid 43381540)
4. Hoke M, Kyrle PA, Minar E, et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005; 94: 787-790. (Pubitemid 41489238)
5. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the Longitudinal Investigation of Thromboembolism Etiology. Am J Med 2004; 117: 19-25. (Pubitemid 38801482)
6. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989; 129: 687-702.
7. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991; 1: 263-276.
8. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).[see comment]. Am J Med 2002; 113: 636-642. (Pubitemid 36015799)
9. Chambless LE, McMahon R, Wu K, et al. Short-term intraindividual variability in hemostasis factors. The ARIC Study. Atherosclerosis Risk in Communities Intraindividual Variability Study. Ann Epidemiol 1992; 2: 723-733.
10. Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-1108. (Pubitemid 27344210)
11. Cushman M, Folsom AR, Wang L, et al. Fibrin fragment D-dimer and the risk of future venous thrombosis. [see comment]. Blood 2003; 101: 1243-1248.
12. Dahm A, Van Hylckama Vlieg A, Bendz B, et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-4392. (Pubitemid 36857803)
13. Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-722. (Pubitemid 24177958)
14. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Wille-brand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
15. van Hylckama Vlieg A, van der Linden IK, Bertina RM, et al. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 3678-3682. (Pubitemid 30412836)
16. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. New Engl J Med 2000; 342: 696-701. (Pubitemid 30131422)
17. Zakai NA, Ohira T, White R, et al. Activated partial thromboplastin time and risk of future venous thromboembolism. Am J Med 2008; 121: 231-238. (Pubitemid 351317918)
18. Knol MJ, van der Tweel I, Grobbee DE, et al. Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int J Epidemiol 2007; 36: 1111-1118.
19. Duering C, Kosch A, Langer C, et al. Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke. Thromb Haemost 2004; 92: 707-712. (Pubitemid 39386694)
20. Amini-Nekoo A, Futers TS, Moia M, et al. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001; 113: 537-543. (Pubitemid 32523166)
21. Andreescu AC, Cushman M, Rosendaal FR. D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study. Thromb Haemost 2002; 87: 47-51. (Pubitemid 34092574)
22. Hoibraaten E, Qvigstad E, Andersen TO, et al. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial. Thromb Haemost 2001; 85: 775-781. (Pubitemid 32421807)